Condition
HCC - Hepatocellular Carcinoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 8 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
8 shownENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese CohortNCT07808164 · 2026-03-19
RECRUITINGA Study of GV20-0251 in Advanced or Refractory Solid TumorsNCT07106827 · 2025-09-04
RECRUITINGStudy of GV20-0251 in Participants With Solid Tumor MalignanciesNCT07070518 · 2025-07-11
RECRUITINGA Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid TumorsNCT07376707 · 2025-06-12
RECRUITINGPROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic StudiesNCT04371042 · 2019-09-01
RECRUITINGEpalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and DiabetesNCT07557914 · 2026-10-01
NOT_YET_RECRUITINGUniversal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung CancerNCT06653023 · 2024-10-23
SUSPENDEDStudy of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid TumorsNCT05651022 · 2023-02-28
ACTIVE_NOT_RECRUITINGCommon interventions
Leading sponsors
Trial status mix
RECRUITING5
ACTIVE_NOT_RECRUITING1
NOT_YET_RECRUITING1
SUSPENDED1
Phase mix
PHASE14
PHASE23
EARLY_PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.